Method for cancer immunotherapy
AssigneesInternational Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
InventorsToshio Nishihara, Masashi Gotoh
Life of this patent
Estimating the term…
Abstract
A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
Claims6
A method for treating cancer, the method comprising:
- administering to a subject in need thereof who is positive for HLA-A24 and positive for WT1 protein a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof;
- wherein formula (1) is:
- wherein X is a tyrosine residue or a methionine residue;
- each of Y and Z is independently selected from the group consisting of a single bond and a divalent peptide group consisting of 1-10 amino acid residues,
- R1 is hydrogen or alkyl,
- R2 is hydroxyl, amino, alkylamino or dialkylamino,
- R3 is hydrogen, alkyl, amino, alkylamino, dialkylamino or substituted or unsubstituted alkylcarbonylamino,
- R4 is hydrogen, alkyl, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or a group of formula (2):
- wherein:
- W is an amino acid residue,
- m is 1 or 2, and
- n is an integer of 0-2,
- with the proviso that when n is 0, then R3 is hydrogen or alkyl.
Dependencies are inferred from the claim text.